[
  {
    "ts": null,
    "headline": "Podcast: Trump Sends More Tariff Letters; Nasdaq Climbs to Record",
    "summary": "Elsewhere in financial markets, drugmaker Merck strikes a roughly $10 billion deal to buy Verona Pharma. The Justice Department’s criminal healthcare-fraud unit investigates UnitedHealth’s Medicare billing practices.",
    "url": "https://finnhub.io/api/news?id=59080d3b5bdf05c7e628331374714a573a806354444b10e5666e8c67e45edb70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752100513,
      "headline": "Podcast: Trump Sends More Tariff Letters; Nasdaq Climbs to Record",
      "id": 135855386,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Elsewhere in financial markets, drugmaker Merck strikes a roughly $10 billion deal to buy Verona Pharma. The Justice Department’s criminal healthcare-fraud unit investigates UnitedHealth’s Medicare billing practices.",
      "url": "https://finnhub.io/api/news?id=59080d3b5bdf05c7e628331374714a573a806354444b10e5666e8c67e45edb70"
    }
  },
  {
    "ts": null,
    "headline": "PRESS DIGEST-British Business - July 10",
    "summary": "July 10 - The following are the top stories onthe business pages of British newspapers. Reuters has notverified these stories and does not vouch for their accuracy. ...",
    "url": "https://finnhub.io/api/news?id=40d89f14d30e52342c751ea5f2c004e473f2fa7d9a23d627d747d11d44dd6229",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752099497,
      "headline": "PRESS DIGEST-British Business - July 10",
      "id": 135839979,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "July 10 - The following are the top stories onthe business pages of British newspapers. Reuters has notverified these stories and does not vouch for their accuracy. ...",
      "url": "https://finnhub.io/api/news?id=40d89f14d30e52342c751ea5f2c004e473f2fa7d9a23d627d747d11d44dd6229"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Rises Higher Than Market: Key Facts",
    "summary": "Merck (MRK) closed the most recent trading day at $83.71, moving +2.88% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=41283ef6777fc8bb7ecb7e3bf43aa592babed7b495ff1c1f5059fdfedcb50542",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752097804,
      "headline": "Merck (MRK) Rises Higher Than Market: Key Facts",
      "id": 135855985,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) closed the most recent trading day at $83.71, moving +2.88% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=41283ef6777fc8bb7ecb7e3bf43aa592babed7b495ff1c1f5059fdfedcb50542"
    }
  },
  {
    "ts": null,
    "headline": "Merck will have 'a lot more work to do' after Verona deal",
    "summary": "Merck (MRK) is spending about $10 billion to acquire Verona Pharma (VRNA) as the company looks to fill future revenue gaps. Evan Seigerman, managing director of biopharma equity research at BMO Capital Markets, joins Market Domination Overtime to discuss what the deal signals about Merck's strategy beyond oncology and how it ties into the upcoming Keytruda patent loss. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
    "url": "https://finnhub.io/api/news?id=e1076781438591c074c3326481ac27d38e13a1fd14c42c39da472c404e62f5eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752095030,
      "headline": "Merck will have 'a lot more work to do' after Verona deal",
      "id": 135841438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) is spending about $10 billion to acquire Verona Pharma (VRNA) as the company looks to fill future revenue gaps. Evan Seigerman, managing director of biopharma equity research at BMO Capital Markets, joins Market Domination Overtime to discuss what the deal signals about Merck's strategy beyond oncology and how it ties into the upcoming Keytruda patent loss. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
      "url": "https://finnhub.io/api/news?id=e1076781438591c074c3326481ac27d38e13a1fd14c42c39da472c404e62f5eb"
    }
  },
  {
    "ts": null,
    "headline": "How major US stock indexes fared Wednesday, 7/9/2025",
    "summary": "Stocks closed higher on Wall Street as the Trump administration sought to win more deals with global trading partners. The S&P 500 rose 0.6% Wednesday. The Dow Jones Industrial Average added 0.5%, and the Nasdaq composite rose 0.9%.",
    "url": "https://finnhub.io/api/news?id=d2775c62b9504becfd9f137a2b0df5a9bd9c816df6bfb9fc05f011fdde73aa68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752092161,
      "headline": "How major US stock indexes fared Wednesday, 7/9/2025",
      "id": 135855989,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Stocks closed higher on Wall Street as the Trump administration sought to win more deals with global trading partners. The S&P 500 rose 0.6% Wednesday. The Dow Jones Industrial Average added 0.5%, and the Nasdaq composite rose 0.9%.",
      "url": "https://finnhub.io/api/news?id=d2775c62b9504becfd9f137a2b0df5a9bd9c816df6bfb9fc05f011fdde73aa68"
    }
  },
  {
    "ts": null,
    "headline": "Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps",
    "summary": "Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a >50% reduction",
    "url": "https://finnhub.io/api/news?id=2bde2941840b6fd39077ade3b9f1609ad103f15ef4a242a9e803c62915a35523",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752086832,
      "headline": "Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps",
      "id": 135839040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a >50% reduction",
      "url": "https://finnhub.io/api/news?id=2bde2941840b6fd39077ade3b9f1609ad103f15ef4a242a9e803c62915a35523"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Wednesday Afternoon",
    "summary": "Health care stocks were edging lower Wednesday afternoon, with the NYSE Health Care Index and the He",
    "url": "https://finnhub.io/api/news?id=8e826d2ff10d79664071a6d71678cda1e830b4741b9215c43a1dc84b8b8221c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752084087,
      "headline": "Sector Update: Health Care Stocks Softer Wednesday Afternoon",
      "id": 135837174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks were edging lower Wednesday afternoon, with the NYSE Health Care Index and the He",
      "url": "https://finnhub.io/api/news?id=8e826d2ff10d79664071a6d71678cda1e830b4741b9215c43a1dc84b8b8221c9"
    }
  },
  {
    "ts": null,
    "headline": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
    "summary": "Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda. The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare diseases and obesity. Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data compiled by LSEG, up 7% from year-ago levels and the highest year-to-date total since 2023.",
    "url": "https://finnhub.io/api/news?id=aa71f0be0003cfe114ac843836c74786c4f8fe821089df0c9499277cb095e9cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752083138,
      "headline": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
      "id": 135855739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda. The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare diseases and obesity. Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data compiled by LSEG, up 7% from year-ago levels and the highest year-to-date total since 2023.",
      "url": "https://finnhub.io/api/news?id=aa71f0be0003cfe114ac843836c74786c4f8fe821089df0c9499277cb095e9cc"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Indexes Rise As Nvidia Hits $4 Trillion Mark; Contender For Fed Leader Emerges (Live Coverage)",
    "summary": "The Dow Jones Index rose Wednesday ahead of the Fed minutes. Nvidia set a new high, and hit the $4 trillion mark in valuation.",
    "url": "https://finnhub.io/api/news?id=ca52d0644cad0c162af692b163559715a5d900d9d6d1bf1c809f0cf5a7a68ec5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752078322,
      "headline": "Stock Market Today: Indexes Rise As Nvidia Hits $4 Trillion Mark; Contender For Fed Leader Emerges (Live Coverage)",
      "id": 135835519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Dow Jones Index rose Wednesday ahead of the Fed minutes. Nvidia set a new high, and hit the $4 trillion mark in valuation.",
      "url": "https://finnhub.io/api/news?id=ca52d0644cad0c162af692b163559715a5d900d9d6d1bf1c809f0cf5a7a68ec5"
    }
  },
  {
    "ts": null,
    "headline": "Trump's newest tariffs, Merck & Verona, X CEO resigns",
    "summary": "Yahoo Finance's John Hyland recaps some of the top stories on Wall Street in under 60 seconds on this episode of Market Minute. President Trump has announced new country-specific tariff rates for Algeria, Libya, Iraq, and the Philippines. Merck (MRK) is buying Verona Pharma (VRNA) in a $10 billion deal. Linda Yaccarino is stepping down as CEO of X (formerly Twitter) after two years leading the social media platform owned by Elon Musk. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=ae733eb62210d6d6462fb1832dbe733e1111529f0184cf81363f6badb1d40224",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752081580,
      "headline": "Trump's newest tariffs, Merck & Verona, X CEO resigns",
      "id": 135835849,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Yahoo Finance's John Hyland recaps some of the top stories on Wall Street in under 60 seconds on this episode of Market Minute. President Trump has announced new country-specific tariff rates for Algeria, Libya, Iraq, and the Philippines. Merck (MRK) is buying Verona Pharma (VRNA) in a $10 billion deal. Linda Yaccarino is stepping down as CEO of X (formerly Twitter) after two years leading the social media platform owned by Elon Musk. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=ae733eb62210d6d6462fb1832dbe733e1111529f0184cf81363f6badb1d40224"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Climbs After Verona Deal - Health Care Roundup",
    "summary": "Health Care Climbs After Verona Deal - Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=4704c5ea6f976b0f4f11bc4cc5bc6b780a8f3d3dee059a6bdae692c4e7805aea",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752080940,
      "headline": "Health Care Climbs After Verona Deal - Health Care Roundup",
      "id": 135859326,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Health Care Climbs After Verona Deal - Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=4704c5ea6f976b0f4f11bc4cc5bc6b780a8f3d3dee059a6bdae692c4e7805aea"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Rises, Nasdaq At Record High As Nvidia Hits $4 Trillion Mark",
    "summary": "Stock Market Today: Dow Rises, Nasdaq At Record High As Nvidia Hits $4 Trillion Mark",
    "url": "https://finnhub.io/api/news?id=5c54b3b1f892e46880352bf9998bf64dee63f85771e764706e7298d36a60a7cb",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752079116,
      "headline": "Stock Market Today: Dow Rises, Nasdaq At Record High As Nvidia Hits $4 Trillion Mark",
      "id": 135854769,
      "image": "",
      "related": "MRK",
      "source": "DowJones",
      "summary": "Stock Market Today: Dow Rises, Nasdaq At Record High As Nvidia Hits $4 Trillion Mark",
      "url": "https://finnhub.io/api/news?id=5c54b3b1f892e46880352bf9998bf64dee63f85771e764706e7298d36a60a7cb"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "1130 ET – Merck isn’t likely to face any competing offers to its $10 billion deal to buy Verona Pharma, analysts at Truist say.  In a note, Truist says the $107 per share takeover of Verona is a pleasant surprise.  The analysts say they and investors they had spoken with believe the more than 400% increase in Verona’s valuation during the past 12 months has pushed the company across the affordability threshold for many potential acquirers.",
    "url": "https://finnhub.io/api/news?id=711d0d3f74a7d8572a537ed08a60dcbfa6b17fe8442b24f90add64df9b654b9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752078540,
      "headline": "Health Care Roundup: Market Talk",
      "id": 135835850,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "1130 ET – Merck isn’t likely to face any competing offers to its $10 billion deal to buy Verona Pharma, analysts at Truist say.  In a note, Truist says the $107 per share takeover of Verona is a pleasant surprise.  The analysts say they and investors they had spoken with believe the more than 400% increase in Verona’s valuation during the past 12 months has pushed the company across the affordability threshold for many potential acquirers.",
      "url": "https://finnhub.io/api/news?id=711d0d3f74a7d8572a537ed08a60dcbfa6b17fe8442b24f90add64df9b654b9d"
    }
  },
  {
    "ts": null,
    "headline": "European Equities Close Higher in Wednesday Trading, Bank Stocks Rally",
    "summary": "The European stock markets closed higher in Wednesday trading as the Stoxx Europe 600 rose 0.73%, Ge",
    "url": "https://finnhub.io/api/news?id=84999e986a15851917ef9c39fb1d67cd6ac954267c9912db327e289a79387522",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752077415,
      "headline": "European Equities Close Higher in Wednesday Trading, Bank Stocks Rally",
      "id": 135835851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The European stock markets closed higher in Wednesday trading as the Stoxx Europe 600 rose 0.73%, Ge",
      "url": "https://finnhub.io/api/news?id=84999e986a15851917ef9c39fb1d67cd6ac954267c9912db327e289a79387522"
    }
  },
  {
    "ts": null,
    "headline": "Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma",
    "summary": "Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma",
    "url": "https://finnhub.io/api/news?id=c45bcf5b029bff6a4546cc5395fc29e987fdcbfdc6b7ee02bc309d38078d3394",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752077353,
      "headline": "Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma",
      "id": 135859305,
      "image": "",
      "related": "MRK",
      "source": "DowJones",
      "summary": "Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma",
      "url": "https://finnhub.io/api/news?id=c45bcf5b029bff6a4546cc5395fc29e987fdcbfdc6b7ee02bc309d38078d3394"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Buy Verona Pharma for Around $10 Billion",
    "summary": "Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years. Keytruda, a top-selling cancer drug, will be coming off patent in 2028. Bloomberg's Damian Garde reports.",
    "url": "https://finnhub.io/api/news?id=a6798224cecee4386973e9af2d8ba12954ecd970ec7ae0e691d336ce8111f322",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752077256,
      "headline": "Merck to Buy Verona Pharma for Around $10 Billion",
      "id": 135835852,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years. Keytruda, a top-selling cancer drug, will be coming off patent in 2028. Bloomberg's Damian Garde reports.",
      "url": "https://finnhub.io/api/news?id=a6798224cecee4386973e9af2d8ba12954ecd970ec7ae0e691d336ce8111f322"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Nvidia, AES, WPP, and More",
    "summary": "Continuing questions about the impact of Trump administration tariffs caused U.S. equities to be higher but little changed at midday.",
    "url": "https://finnhub.io/api/news?id=93b3e91431ff2d8fe35599dd60107276fd45a6661eb85a60f7ad971227ec3eae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752077139,
      "headline": "Top Stock Movers Now: Nvidia, AES, WPP, and More",
      "id": 135835523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Continuing questions about the impact of Trump administration tariffs caused U.S. equities to be higher but little changed at midday.",
      "url": "https://finnhub.io/api/news?id=93b3e91431ff2d8fe35599dd60107276fd45a6661eb85a60f7ad971227ec3eae"
    }
  },
  {
    "ts": null,
    "headline": "Dow's 225-point rally highlighted by gains in shares of Boeing, Merck",
    "summary": "Dow's 225-point rally highlighted by gains in shares of Boeing, Merck",
    "url": "https://finnhub.io/api/news?id=b837ec7fc99f2da3c66acb987df4b08e9bd6eed63d5e9730d6e007874472ea6e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752076500,
      "headline": "Dow's 225-point rally highlighted by gains in shares of Boeing, Merck",
      "id": 135859327,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Dow's 225-point rally highlighted by gains in shares of Boeing, Merck",
      "url": "https://finnhub.io/api/news?id=b837ec7fc99f2da3c66acb987df4b08e9bd6eed63d5e9730d6e007874472ea6e"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Nvidia Hits $4 Trillion Market Cap; Merck to Acquire Verona for $10 Billion",
    "summary": "All three major US stock indexes were up in late-morning trading Wednesday as investors wait for mor",
    "url": "https://finnhub.io/api/news?id=07651c6502f62e46fa28a59d7ef909c3eddc8e55e500c2424677cf3b88c400cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752074771,
      "headline": "Top Midday Stories: Nvidia Hits $4 Trillion Market Cap; Merck to Acquire Verona for $10 Billion",
      "id": 135835595,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Wednesday as investors wait for mor",
      "url": "https://finnhub.io/api/news?id=07651c6502f62e46fa28a59d7ef909c3eddc8e55e500c2424677cf3b88c400cd"
    }
  },
  {
    "ts": null,
    "headline": "What You Need To Know Ahead of Merck's Earnings Release",
    "summary": "Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.",
    "url": "https://finnhub.io/api/news?id=b68058098ae2d302ab149ba7ef1a2550758e667252098335a2290386749270cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752074241,
      "headline": "What You Need To Know Ahead of Merck's Earnings Release",
      "id": 135835855,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.",
      "url": "https://finnhub.io/api/news?id=b68058098ae2d302ab149ba7ef1a2550758e667252098335a2290386749270cb"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Buy Verona Pharma in $10 Billion Deal",
    "summary": "The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.",
    "url": "https://finnhub.io/api/news?id=c1a418572985bcd2090fbc78fdc9d6e9540f2856254089d4c3ecb929000b1bb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752071760,
      "headline": "Merck to Buy Verona Pharma in $10 Billion Deal",
      "id": 135835856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The move bolsters Merck’s lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.",
      "url": "https://finnhub.io/api/news?id=c1a418572985bcd2090fbc78fdc9d6e9540f2856254089d4c3ecb929000b1bb5"
    }
  },
  {
    "ts": null,
    "headline": "Merck Is Buying Lung-Disease Biotech in $10 Billion Deal",
    "summary": "Merck  said Wednesday it would pay $10 billion to buy the biotech  Verona Pharma  which sells a new lung-disease drug that analysts expect to be a blockbuster.  The deal is Merck’s biggest acquisition since 2021, and comes amid a persistent stock slide.  Investors are increasingly worried about what happens after the U.S. patents protecting Keytruda, Merck’s top-selling cancer drug, expire in 2028.",
    "url": "https://finnhub.io/api/news?id=80719fef6e302fd95c872ccaead9477e9c2b590683ed9f5889a12f376b60c62b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752070260,
      "headline": "Merck Is Buying Lung-Disease Biotech in $10 Billion Deal",
      "id": 135835857,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck  said Wednesday it would pay $10 billion to buy the biotech  Verona Pharma  which sells a new lung-disease drug that analysts expect to be a blockbuster.  The deal is Merck’s biggest acquisition since 2021, and comes amid a persistent stock slide.  Investors are increasingly worried about what happens after the U.S. patents protecting Keytruda, Merck’s top-selling cancer drug, expire in 2028.",
      "url": "https://finnhub.io/api/news?id=80719fef6e302fd95c872ccaead9477e9c2b590683ed9f5889a12f376b60c62b"
    }
  },
  {
    "ts": null,
    "headline": "Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B",
    "summary": "Merck is paying about $10 billion for Verona Pharma, expanding its respiratory disease drug portfolio.",
    "url": "https://finnhub.io/api/news?id=6931d37169df426ff595180384dc852fe5f52cc71a886f7606c4a2b9d9c3223c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752069892,
      "headline": "Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B",
      "id": 135835858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck is paying about $10 billion for Verona Pharma, expanding its respiratory disease drug portfolio.",
      "url": "https://finnhub.io/api/news?id=6931d37169df426ff595180384dc852fe5f52cc71a886f7606c4a2b9d9c3223c"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Wednesday: Freeport-McMoRan, AES, Merck, Fair Isaac",
    "summary": "↘️ Freeport-McMoRan (FCX): The miner's shares fell, partly paring Tuesday's gains that came after President Trump said he would impose 50% tariffs on copper. Shares of overseas copper producers such as️ Glencore (UK:GLEN) and Anglo American (UK:AAL) declined Wednesday.",
    "url": "https://finnhub.io/api/news?id=22f9d3c043c5cf5cc752ca081cd4e3fca61e2571b556781d3807dda088a8d8fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752069575,
      "headline": "Stocks to Watch Wednesday: Freeport-McMoRan, AES, Merck, Fair Isaac",
      "id": 135835760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "↘️ Freeport-McMoRan (FCX): The miner's shares fell, partly paring Tuesday's gains that came after President Trump said he would impose 50% tariffs on copper. Shares of overseas copper producers such as️ Glencore (UK:GLEN) and Anglo American (UK:AAL) declined Wednesday.",
      "url": "https://finnhub.io/api/news?id=22f9d3c043c5cf5cc752ca081cd4e3fca61e2571b556781d3807dda088a8d8fa"
    }
  },
  {
    "ts": null,
    "headline": "Pharma latest: Merck to acquire Verona, Trump pharma tariffs",
    "summary": "Yahoo Finance Senior Reporter Anjalee Khemlani joins Morning Brief to discuss Merck's (MRK) pending $10 billion acquisition of Verona Pharma (VRNA), expected to close in the fourth quarter this year, as well as the latest developments on President Trump's potential tariffs on pharmaceuticals. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=8be1701a91bb80c7e29f1a96f0c5e61281463230393f4b31ffe5204d539dcf3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752068810,
      "headline": "Pharma latest: Merck to acquire Verona, Trump pharma tariffs",
      "id": 135835860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Reporter Anjalee Khemlani joins Morning Brief to discuss Merck's (MRK) pending $10 billion acquisition of Verona Pharma (VRNA), expected to close in the fourth quarter this year, as well as the latest developments on President Trump's potential tariffs on pharmaceuticals. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=8be1701a91bb80c7e29f1a96f0c5e61281463230393f4b31ffe5204d539dcf3a"
    }
  },
  {
    "ts": null,
    "headline": "Tariff Turbulence and Overbought Tech Mark Post-Holiday Trading",
    "summary": "While the prevailing bullish sentiment and the market's resilience to tariff news offer encouraging signs, the emergence of short-term caution flags like an overbought Nasdaq and extreme greed sentiment suggest a need for selective and strategic positioning.",
    "url": "https://finnhub.io/api/news?id=e083740e3c01946af9006ad600e7cf6db958780c60e8e4b9fc9563cc83286c6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752068040,
      "headline": "Tariff Turbulence and Overbought Tech Mark Post-Holiday Trading",
      "id": 135835861,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "While the prevailing bullish sentiment and the market's resilience to tariff news offer encouraging signs, the emergence of short-term caution flags like an overbought Nasdaq and extreme greed sentiment suggest a need for selective and strategic positioning.",
      "url": "https://finnhub.io/api/news?id=e083740e3c01946af9006ad600e7cf6db958780c60e8e4b9fc9563cc83286c6b"
    }
  },
  {
    "ts": null,
    "headline": "Merck Faces Multiple Challenges: Will It Steer Through Successfully?",
    "summary": "MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.",
    "url": "https://finnhub.io/api/news?id=3913d662aa4220ce980be59df562b1a9635337751fca0692b11b698b88d7d6f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067440,
      "headline": "Merck Faces Multiple Challenges: Will It Steer Through Successfully?",
      "id": 135835679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.",
      "url": "https://finnhub.io/api/news?id=3913d662aa4220ce980be59df562b1a9635337751fca0692b11b698b88d7d6f9"
    }
  },
  {
    "ts": null,
    "headline": "Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?",
    "summary": "BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.",
    "url": "https://finnhub.io/api/news?id=7156988e2ac9d6348b73629f02770593e63008405c02fd4ad3cb311de6cf08d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067200,
      "headline": "Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?",
      "id": 135835864,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.",
      "url": "https://finnhub.io/api/news?id=7156988e2ac9d6348b73629f02770593e63008405c02fd4ad3cb311de6cf08d3"
    }
  },
  {
    "ts": null,
    "headline": "GSK's Specialty Medicines Unit on a Strong Footing: Here's Why",
    "summary": "GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.",
    "url": "https://finnhub.io/api/news?id=ffae2227cbb8fa757ed1b4939844a5856b7e0057ba2554b69fb8d0d533b629ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067140,
      "headline": "GSK's Specialty Medicines Unit on a Strong Footing: Here's Why",
      "id": 135835866,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.",
      "url": "https://finnhub.io/api/news?id=ffae2227cbb8fa757ed1b4939844a5856b7e0057ba2554b69fb8d0d533b629ca"
    }
  },
  {
    "ts": null,
    "headline": "Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck",
    "summary": "VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.",
    "url": "https://finnhub.io/api/news?id=16a0ec4ea00adf94ea44aea98aaef434dd1c577df6835043c52dfcfc4f21af13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067140,
      "headline": "Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck",
      "id": 135835680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.",
      "url": "https://finnhub.io/api/news?id=16a0ec4ea00adf94ea44aea98aaef434dd1c577df6835043c52dfcfc4f21af13"
    }
  },
  {
    "ts": null,
    "headline": "Boeing, Merck share gains contribute to Dow's 111-point jump",
    "summary": "Boeing, Merck share gains contribute to Dow's 111-point jump",
    "url": "https://finnhub.io/api/news?id=af65dfbcf8ea980ab29a282c49d288e4b1b4327035812922c772b326c2c631cc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752067020,
      "headline": "Boeing, Merck share gains contribute to Dow's 111-point jump",
      "id": 135859328,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Boeing, Merck share gains contribute to Dow's 111-point jump",
      "url": "https://finnhub.io/api/news?id=af65dfbcf8ea980ab29a282c49d288e4b1b4327035812922c772b326c2c631cc"
    }
  },
  {
    "ts": null,
    "headline": "Merck's stock among S&P 500's leaders after $10 billion Verona Pharma deal",
    "summary": "Merck's stock among S&P 500's leaders after $10 billion Verona Pharma deal",
    "url": "https://finnhub.io/api/news?id=032adee0b0708f070474213a16b32a6399019b205abcc62e28815f22435f4261",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752066903,
      "headline": "Merck's stock among S&P 500's leaders after $10 billion Verona Pharma deal",
      "id": 135859329,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck's stock among S&P 500's leaders after $10 billion Verona Pharma deal",
      "url": "https://finnhub.io/api/news?id=032adee0b0708f070474213a16b32a6399019b205abcc62e28815f22435f4261"
    }
  },
  {
    "ts": null,
    "headline": "Undercovered Dozen: Roku, Merck, Chevron And More",
    "summary": "The Undercovered Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential.",
    "url": "https://finnhub.io/api/news?id=7c1e492c607129e46b9a1f173b97e401e917d74d9c80ea70a2ea83e146cc44be",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752065995,
      "headline": "Undercovered Dozen: Roku, Merck, Chevron And More",
      "id": 135835356,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195513748/image_2195513748.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "The Undercovered Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential.",
      "url": "https://finnhub.io/api/news?id=7c1e492c607129e46b9a1f173b97e401e917d74d9c80ea70a2ea83e146cc44be"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Buy Verona Pharma for About $10B",
    "summary": "Merck agreed to buy respiratory drugmaker Verona for about $10 billion as part of its ongoing search for ways to fill the Keytruda-sized hole that will emerge over the next few years....",
    "url": "https://finnhub.io/api/news?id=43c3011cd4c9ff5e6f1daf160fe8f7a8fcc9cc666eb84fa764c87281320bb3f8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752064215,
      "headline": "Merck to Buy Verona Pharma for About $10B",
      "id": 135835170,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck agreed to buy respiratory drugmaker Verona for about $10 billion as part of its ongoing search for ways to fill the Keytruda-sized hole that will emerge over the next few years....",
      "url": "https://finnhub.io/api/news?id=43c3011cd4c9ff5e6f1daf160fe8f7a8fcc9cc666eb84fa764c87281320bb3f8"
    }
  },
  {
    "ts": null,
    "headline": "Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue",
    "summary": "Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my updated look at MRK and VRNA stock.",
    "url": "https://finnhub.io/api/news?id=992bb5eebb0c98ea4bcfa1d1cc04bd98cd5e59d34eeaa42ad248129da9b16a4a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752062381,
      "headline": "Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue",
      "id": 135835081,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my updated look at MRK and VRNA stock.",
      "url": "https://finnhub.io/api/news?id=992bb5eebb0c98ea4bcfa1d1cc04bd98cd5e59d34eeaa42ad248129da9b16a4a"
    }
  },
  {
    "ts": null,
    "headline": "Merck dives into COPD treatments with $10 billion purchase of Verona Pharma",
    "summary": "Merck dives into COPD treatments with $10 billion purchase of Verona Pharma",
    "url": "https://finnhub.io/api/news?id=5efeb7454adf68d2817d2ca01e220e7ca694f9c8965335737f35eed1e60efb43",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752055260,
      "headline": "Merck dives into COPD treatments with $10 billion purchase of Verona Pharma",
      "id": 135859331,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck dives into COPD treatments with $10 billion purchase of Verona Pharma",
      "url": "https://finnhub.io/api/news?id=5efeb7454adf68d2817d2ca01e220e7ca694f9c8965335737f35eed1e60efb43"
    }
  },
  {
    "ts": null,
    "headline": "Boeing, Merck share gains contribute to Dow's 275-point climb",
    "summary": "Boeing, Merck share gains contribute to Dow's 275-point climb",
    "url": "https://finnhub.io/api/news?id=4a9d6e39341a888f6ff998bb43bd9d5b9189a90b557cb9988fd876b8552f7b06",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752054300,
      "headline": "Boeing, Merck share gains contribute to Dow's 275-point climb",
      "id": 135859332,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Boeing, Merck share gains contribute to Dow's 275-point climb",
      "url": "https://finnhub.io/api/news?id=4a9d6e39341a888f6ff998bb43bd9d5b9189a90b557cb9988fd876b8552f7b06"
    }
  },
  {
    "ts": null,
    "headline": "Merck: confirms acquisition of Verona Pharma",
    "summary": "Merck confirms the acquisition of Verona Pharma, a biopharmaceutical company specializing in respiratory diseases.Merck, through a subsidiary, will acquire Verona Pharma for $107 per American...",
    "url": "https://finnhub.io/api/news?id=10848aefa84516d09d51398ce2bd1e345870e1154413e622d993f86ec752b963",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752049403,
      "headline": "Merck: confirms acquisition of Verona Pharma",
      "id": 135833187,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck confirms the acquisition of Verona Pharma, a biopharmaceutical company specializing in respiratory diseases.Merck, through a subsidiary, will acquire Verona Pharma for $107 per American...",
      "url": "https://finnhub.io/api/news?id=10848aefa84516d09d51398ce2bd1e345870e1154413e622d993f86ec752b963"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Copper Retreats, Crude Oil Gains",
    "summary": "Wall Street Breakfast Podcast: Copper Retreats, Crude Oil Gains",
    "url": "https://finnhub.io/api/news?id=d13c0fd7bd9bea9d332dbd29920dcf60d2d9e801da166cb3231e75c76bfcabb5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752049080,
      "headline": "Wall Street Breakfast Podcast: Copper Retreats, Crude Oil Gains",
      "id": 135833163,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d13c0fd7bd9bea9d332dbd29920dcf60d2d9e801da166cb3231e75c76bfcabb5"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Buy Verona Pharma in $10 Billion Deal -- Update",
    "summary": "By Colin Kellaher Merck & Co. has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive pulmonary disease treatment Ohtuvayre as it braces for...",
    "url": "https://finnhub.io/api/news?id=8493e3c11b557f504a5d265b3e6f8607d4f864d5cbcf0a761e8e5c9b20ea6428",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752045548,
      "headline": "Merck to Buy Verona Pharma in $10 Billion Deal -- Update",
      "id": 135832740,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co. has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive pulmonary disease treatment Ohtuvayre as it braces for...",
      "url": "https://finnhub.io/api/news?id=8493e3c11b557f504a5d265b3e6f8607d4f864d5cbcf0a761e8e5c9b20ea6428"
    }
  },
  {
    "ts": null,
    "headline": "Merck spends $10 billion for Verona, gaining access to its COPD medication",
    "summary": "Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. The deal gives Merck access to Verona Pharma's new chronic...",
    "url": "https://finnhub.io/api/news?id=cfa8e541e684599f2c34f8dcbd2341c81ebfdc4ed07f0acbef20278e366d6a2d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752044825,
      "headline": "Merck spends $10 billion for Verona, gaining access to its COPD medication",
      "id": 135833170,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. The deal gives Merck access to Verona Pharma's new chronic...",
      "url": "https://finnhub.io/api/news?id=cfa8e541e684599f2c34f8dcbd2341c81ebfdc4ed07f0acbef20278e366d6a2d"
    }
  },
  {
    "ts": null,
    "headline": "Verona Pharma Shares Pop Premarket on Report of Merck Takeover",
    "summary": "By Colin Kellaher Verona Pharma shares jumped in premarket trading Wednesday after the Financial Times reported that Merck & Co. is nearing a $10 billion deal to buy the U.K. drugmaker. Under...",
    "url": "https://finnhub.io/api/news?id=8db3e107bf8cd2db2f23b378a3961846bea284758b639b397f4bf2b491f4b739",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752043456,
      "headline": "Verona Pharma Shares Pop Premarket on Report of Merck Takeover",
      "id": 135832565,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Verona Pharma shares jumped in premarket trading Wednesday after the Financial Times reported that Merck & Co. is nearing a $10 billion deal to buy the U.K. drugmaker. Under...",
      "url": "https://finnhub.io/api/news?id=8db3e107bf8cd2db2f23b378a3961846bea284758b639b397f4bf2b491f4b739"
    }
  },
  {
    "ts": null,
    "headline": "Merck to acquire Verona Pharma for $10 billion",
    "summary": "Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of...",
    "url": "https://finnhub.io/api/news?id=daf2b13b39879a45d193a32d1725d62da81de7ecd37477426983d572b1e84413",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752043209,
      "headline": "Merck to acquire Verona Pharma for $10 billion",
      "id": 135832556,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of...",
      "url": "https://finnhub.io/api/news?id=daf2b13b39879a45d193a32d1725d62da81de7ecd37477426983d572b1e84413"
    }
  },
  {
    "ts": null,
    "headline": "Merck Nears $10 Billion Takeover of Verona Pharma, FT Says, Citing Sources",
    "summary": "Merck is nearing a roughly $10 billion deal to buy lung disease-focused drugmaker Verona Pharma, the Financial Times reports, citing people familiar with the matter. --Merck would pay $107 per...",
    "url": "https://finnhub.io/api/news?id=f3c6762ce5b13f8868db9c909651e0880af6dbc10173482358b9710f97c83881",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752042694,
      "headline": "Merck Nears $10 Billion Takeover of Verona Pharma, FT Says, Citing Sources",
      "id": 135832490,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck is nearing a roughly $10 billion deal to buy lung disease-focused drugmaker Verona Pharma, the Financial Times reports, citing people familiar with the matter. --Merck would pay $107 per...",
      "url": "https://finnhub.io/api/news?id=f3c6762ce5b13f8868db9c909651e0880af6dbc10173482358b9710f97c83881"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade",
    "summary": "Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseasesMerck to hold investor call at 8 a.m. ET...",
    "url": "https://finnhub.io/api/news?id=4c1bfd2c464f34c02be70128a3043d4ad44a9b80587ad3850cd96e76e2fc2eba",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752042665,
      "headline": "Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade",
      "id": 135832487,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseasesMerck to hold investor call at 8 a.m. ET...",
      "url": "https://finnhub.io/api/news?id=4c1bfd2c464f34c02be70128a3043d4ad44a9b80587ad3850cd96e76e2fc2eba"
    }
  },
  {
    "ts": null,
    "headline": "Merck nears about $10 billion deal for London-based lung therapy firm Verona, FT reports",
    "summary": "Merck will pay $107 per American depository share for Verona, the report said, citing three people familiar with the matter.  It would be Merck's largest takeover since 2023.  Merck and London-based Verona didn't immediately respond to Reuters requests for comment.",
    "url": "https://finnhub.io/api/news?id=82f1897a28d5ff9131327345cc4a2475bb9e8752f8d748ed03baa53ebe7b5206",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752037741,
      "headline": "Merck nears about $10 billion deal for London-based lung therapy firm Verona, FT reports",
      "id": 135829854,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck will pay $107 per American depository share for Verona, the report said, citing three people familiar with the matter.  It would be Merck's largest takeover since 2023.  Merck and London-based Verona didn't immediately respond to Reuters requests for comment.",
      "url": "https://finnhub.io/api/news?id=82f1897a28d5ff9131327345cc4a2475bb9e8752f8d748ed03baa53ebe7b5206"
    }
  },
  {
    "ts": null,
    "headline": "Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III",
    "summary": "Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May 30 to June 3, featured presentations on two highly anticipated trials for head and neck squamous cell carcinoma/HNSCC. The announcements for these presentations […]",
    "url": "https://finnhub.io/api/news?id=b8c65fb193cf164b604381d19dc2bec9f59a6aaef27a93477b0db1f8a18bff32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752036911,
      "headline": "Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III",
      "id": 135829280,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May 30 to June 3, featured presentations on two highly anticipated trials for head and neck squamous cell carcinoma/HNSCC. The announcements for these presentations […]",
      "url": "https://finnhub.io/api/news?id=b8c65fb193cf164b604381d19dc2bec9f59a6aaef27a93477b0db1f8a18bff32"
    }
  },
  {
    "ts": null,
    "headline": "Merck: could buy Verona Pharma for $10bn",
    "summary": "Merck is in advanced talks to acquire the British respiratory treatment company Verona Pharma, according to the Financial Times. The deal could be worth up to $10bn, valuing the stock at $107, i.e. a...",
    "url": "https://finnhub.io/api/news?id=907e7b19606f5500c87ab9102b39d63f20cf85d6405822c9ea72d95528805a56",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752034827,
      "headline": "Merck: could buy Verona Pharma for $10bn",
      "id": 135831448,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck is in advanced talks to acquire the British respiratory treatment company Verona Pharma, according to the Financial Times. The deal could be worth up to $10bn, valuing the stock at $107, i.e. a...",
      "url": "https://finnhub.io/api/news?id=907e7b19606f5500c87ab9102b39d63f20cf85d6405822c9ea72d95528805a56"
    }
  },
  {
    "ts": null,
    "headline": "Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda",
    "summary": "Merck will buy UK-basedVerona Pharma for about $10 billion, the companies saidon Wednesday, strengthening the U.S. drugmaker's respiratorytreatments as part of efforts to reduce dependence on...",
    "url": "https://finnhub.io/api/news?id=97e4cdaac5bb82bb7a27eb947ceed06d4f19232bf4c2a6ba517fcbdfa1773089",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752025030,
      "headline": "Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda",
      "id": 135833043,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck will buy UK-basedVerona Pharma for about $10 billion, the companies saidon Wednesday, strengthening the U.S. drugmaker's respiratorytreatments as part of efforts to reduce dependence on...",
      "url": "https://finnhub.io/api/news?id=97e4cdaac5bb82bb7a27eb947ceed06d4f19232bf4c2a6ba517fcbdfa1773089"
    }
  },
  {
    "ts": null,
    "headline": "Merck shells out $10 billion for London-based lung therapy firm Verona",
    "summary": "Merck will buy UK-basedVerona Pharma for about $10 billion, the companies saidon Wednesday, strengthening the U.S. firm's respiratorytreatment portfolio in a bid to diversify its revenue...",
    "url": "https://finnhub.io/api/news?id=a30150e0f328ab5d3d096b6689ab4f1817370847376f74b27a4ff127743b2ad4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752025030,
      "headline": "Merck shells out $10 billion for London-based lung therapy firm Verona",
      "id": 135832558,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck will buy UK-basedVerona Pharma for about $10 billion, the companies saidon Wednesday, strengthening the U.S. firm's respiratorytreatment portfolio in a bid to diversify its revenue...",
      "url": "https://finnhub.io/api/news?id=a30150e0f328ab5d3d096b6689ab4f1817370847376f74b27a4ff127743b2ad4"
    }
  },
  {
    "ts": null,
    "headline": "Merck nears $10 billion deal for London-based lung therapy firm Verona, FT reports",
    "summary": "Merck is nearing a $10billion deal to buy lung diseases focussed Verona Pharma, as the U.S. drugmaker is eyeing deals to offset theupcoming patent expiry of its blockbuster cancer drug,...",
    "url": "https://finnhub.io/api/news?id=4d994592784ae783a122d6e3495fc55ee00c6200d69ce378bfb9e6de8498ae56",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752025030,
      "headline": "Merck nears $10 billion deal for London-based lung therapy firm Verona, FT reports",
      "id": 135831938,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck is nearing a $10billion deal to buy lung diseases focussed Verona Pharma, as the U.S. drugmaker is eyeing deals to offset theupcoming patent expiry of its blockbuster cancer drug,...",
      "url": "https://finnhub.io/api/news?id=4d994592784ae783a122d6e3495fc55ee00c6200d69ce378bfb9e6de8498ae56"
    }
  },
  {
    "ts": null,
    "headline": "Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports",
    "summary": "Merck is nearing a roughly$10 billion deal to buy lung disease-focused biotech VeronaPharma, the Financial Times reported on Wednesday. Merck would pay $107 per American depository...",
    "url": "https://finnhub.io/api/news?id=049e33b6ecdc603c8e1cad9ab38fbbb816ce97d062f531602231382835449300",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752025030,
      "headline": "Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports",
      "id": 135828978,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck is nearing a roughly$10 billion deal to buy lung disease-focused biotech VeronaPharma, the Financial Times reported on Wednesday. Merck would pay $107 per American depository...",
      "url": "https://finnhub.io/api/news?id=049e33b6ecdc603c8e1cad9ab38fbbb816ce97d062f531602231382835449300"
    }
  },
  {
    "ts": null,
    "headline": "Merck nears $10 bln deal for respiratory drugmaker Verona- FT",
    "summary": "July 9 -Merck nears $10bn deal for respiratory drugmaker Verona- FTMerck would pay $107 per American Depository Share for Verona - FT...",
    "url": "https://finnhub.io/api/news?id=30958272179d2d14542d5067e77a67962103001145b4d75fc17dce9a0b505e9f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752022629,
      "headline": "Merck nears $10 bln deal for respiratory drugmaker Verona- FT",
      "id": 135828520,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "July 9 -Merck nears $10bn deal for respiratory drugmaker Verona- FTMerck would pay $107 per American Depository Share for Verona - FT...",
      "url": "https://finnhub.io/api/news?id=30958272179d2d14542d5067e77a67962103001145b4d75fc17dce9a0b505e9f"
    }
  }
]